News

The double-blinded, placebo controlled trial is evaluating the use of the monoclonal antibody therapy designed to block chronic inflammation associated with malignant tumor growth. According to the company,

The approval of this indication is now consistent with that of the rest of the world, where alglucosidase alfa manufactured at the 4000L is the only scale available.

Esperante is the investment arm of the C&P Group, a global, privately owned group of life science businesses including Nordic Pharma, a fully-integrated, pan-European pharmaceutical and services company,

Dr. James Andrews, the legendary orthopedic surgeon will be the principal investigator for the study. inVentiv Health Clinical will serve as the Clinical Research Organization (CRO) for the

Under the terms of the agreement, the Company and the University of Leipzig will have 12 months to negotiate a definitive license agreement, and the Company will work

The 12-month option provides an additional $2.1 million to Soligenix to advance OrbeShield as a medical countermeasure (MCM) for the treatment of gastrointestinal acute radiation syndrome (GI ARS).

The approval was given after reviewing results from a large clinical program which included over ten multinational clinical trials and more than 13,000 adults with T2D. The Phase

Darinaparsin is a new mitochondrial-targeted agent under development for the treatment of several hematologic and solid cancers. As part of the amended and restated deal, Solasia secured exclusive

CRT 001 (xamoterol fumarate), a selective partial agonist of the beta-1 adrenergic receptor (B1-ADR), is the lead drug candidate in the portfolio acquired by the company. B1-ADR is